Latest Breaking News On - Advanced melanoma - Page 2 : comparemela.com

Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases

1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. 2. Treatment-related grade ≥ 3 adverse events occurred in 68% of the BRAF V600 mutation-positive cohort (most common being lipase increased creatine phosphokinase increased) and 53% in the BRAFV600 wild-type cohort (anemia and dermatitis acneiform).

Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma

Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.